Last Price
0.072
Today's Change
+0.001 (1.40%)
Day's Change
0.071 - 0.076
Trading Volume
32,544,058
Market Cap
527 Million
Shares Outstanding
7 Billion
Avg Volume
17,788,542
Avg Price (50 Days)
0.09
Avg Price (200 Days)
0.09
PE Ratio
-7.20
EPS
-0.01
Earnings Announcement
28-Feb-2024
Previous Close
0.07
Open
0.07
Day's Range
0.071 - 0.076
Year Range
0.039 - 0.15
Trading Volume
32,544,058
1 Day Change
1.41%
5 Day Change
-4.00%
1 Month Change
-7.69%
3 Month Change
-37.39%
6 Month Change
-19.10%
Ytd Change
-34.55%
1 Year Change
-37.39%
3 Year Change
-78.18%
5 Year Change
323.53%
10 Year Change
505.45%
Max Change
-99.50%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.